Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-453,167
Closed -$1.49M 166
2025
Q2
$1.49M Sell
453,167
-1,891,125
-81% -$6.85M 0.03% 159
2025
Q1
$9.03M Sell
2,344,292
-147,500
-6% -$613K 0.17% 81
2024
Q4
$9.62M Hold
2,491,792
0.17% 72
2024
Q3
$18.3M Buy
2,491,792
+48,524
+2% +$318K 0.29% 51
2024
Q2
$15.8M Buy
2,443,268
+416,476
+21% +$3.31M 0.25% 44
2024
Q1
$21.3M Buy
+2,026,792
New +$16.5M 0.34% 33
2021
Q4
Sell
-519,550
Closed -$11.3M 373
2021
Q3
$11.3M Hold
519,550
0.16% 82
2021
Q2
$12.4M Hold
519,550
0.17% 79
2021
Q1
$7.39M Hold
519,550
0.1% 104
2020
Q4
$4.68M Hold
519,550
0.08% 129
2020
Q3
$3.88M Hold
519,550
0.08% 131
2020
Q2
$4.49M Buy
519,550
+240,000
+86% +$2.07M 0.1% 117
2020
Q1
$1.86M Buy
+279,550
New +$3.57M 0.05% 139

Other funds holding BAK

Howard Marks's BAK Position: Q3 2025 in Review

Howard Marks sold out of Braskem (BAK) in Q3 2025, closing a stake of 453,167 shares — an estimated $1.49M sold.

Howard Marks first reported a position in BAK in Q1 2020 and held it in 13 quarters. The position peaked at $21.3M in Q1 2024. 45 funds tracked by Wall St. Rank hold BAK as of Q3 2025.

  • Howard Marks reported no remaining Braskem position as of Q3 2025 after selling out during the quarter.
  • Howard Marks sold 453,167 Braskem shares in Q3 2025, an estimated $1.49M.
  • Howard Marks first reported a position in Braskem in Q1 2020 and held it in 13 quarters.
  • Howard Marks's Braskem position peaked at $21.3M in Q1 2024.
  • 45 funds tracked by Wall St. Rank held Braskem as of Q3 2025.

Based on Oaktree Capital Management's 13F filing for Q3 2025, filed 13 Nov 2025.